Cava Group's Price Target Raised to $98 by Analysts
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 37 minutes ago
0mins
Should l Buy CAVA?
Source: stocktwits
- Price Target Increase: Baird raised Cava's price target from $88 to $98 while maintaining an 'Outperform' rating, reflecting analysts' confidence in the company's future performance.
- Strong Q1 Performance: Cava reported first-quarter revenue of $434.4 million, a 32.2% year-over-year increase, with same-store sales growth of 9.7%, showcasing the company's success in new restaurant openings and customer traffic growth.
- Analyst Optimism: Stifel analyst Chris O'Cull raised Cava's price target to $105, expecting sustained unit productivity and brand awareness to support the stock's premium valuation, indicating strong market confidence in future growth.
- Retail Sentiment Shift: Retail sentiment for Cava on Stocktwits shifted from 'bullish' to 'extremely bullish', with message volumes significantly increasing, reflecting investor optimism about the company's prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAVA
Wall Street analysts forecast CAVA stock price to fall
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 79.890
Low
60.00
Averages
73.29
High
86.00
Current: 79.890
Low
60.00
Averages
73.29
High
86.00
About CAVA
CAVA Group, Inc. is a category-defining Mediterranean fast-casual restaurant brand. The Company’s Mediterranean cuisine unites taste and health, with a menu that features chef-curated and customizable bowls and pitas. Its dips, spreads, and dressings are centrally produced and sold in grocery stores. Its menu offers a range of dietary preferences, from hearty and indulgent to vegan, vegetarian, gluten-free, dairy-free, paleo, keto, and nut-free diets. Its guests can choose a chef-curated meal or a build-your-own-bowl or pita using its 38 ingredients with over 17.4 billion combinations. It has developed a multi-channel experience that consists of in-restaurant dining, digital pick-up, drive-thru pick-up in select restaurants, delivery, catering, and consumer packaged goods offerings, fully supported by its digital infrastructure. It operates two production facilities: one in Maryland and one in Virginia. It operates in approximately 26 states and the District of Columbia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CAVA Group Reports Strong Q1 Earnings and Upbeat Outlook
- Significant Revenue Growth: CAVA's Q1 revenue surged 32.2% year-on-year to $434.4 million, driven by strong same-store sales and new restaurant openings, showcasing the company's resilience amid economic uncertainty.
- Increased Customer Traffic: The chain experienced a 6.8% rise in guest traffic during the quarter, a notable achievement against a backdrop of cautious consumer spending and geopolitical concerns, indicating successful brand appeal and market positioning.
- Robust Pricing Strategy: CEO Brett Schulman highlighted that CAVA's price increases since 2019 have remained below inflation, playing a crucial role in building customer trust and long-term loyalty while avoiding discounting tactics employed by competitors.
- Optimistic Outlook: CAVA raised its full-year same-restaurant sales forecast to a range of 4.5% to 6.5%, exceeding the previous guidance of 3% to 5%, reflecting strong confidence in future growth and robust market demand.
See More
Cava Group's Price Target Raised to $98 by Analysts
- Price Target Increase: Baird raised Cava's price target from $88 to $98 while maintaining an 'Outperform' rating, reflecting analysts' confidence in the company's future performance.
- Strong Q1 Performance: Cava reported first-quarter revenue of $434.4 million, a 32.2% year-over-year increase, with same-store sales growth of 9.7%, showcasing the company's success in new restaurant openings and customer traffic growth.
- Analyst Optimism: Stifel analyst Chris O'Cull raised Cava's price target to $105, expecting sustained unit productivity and brand awareness to support the stock's premium valuation, indicating strong market confidence in future growth.
- Retail Sentiment Shift: Retail sentiment for Cava on Stocktwits shifted from 'bullish' to 'extremely bullish', with message volumes significantly increasing, reflecting investor optimism about the company's prospects.
See More
Multiple Companies Beat Earnings Estimates, Stock Movements
- Lowe's Earnings Report: Despite slightly beating earnings and revenue estimates in its first-quarter report, Lowe's shares fell nearly 2%, indicating that challenges in the macro housing market are impacting investor sentiment.
- Toll Brothers Strong Performance: Toll Brothers reported fiscal second-quarter earnings of $2.72 per share, surpassing the $2.57 expected by analysts, with revenue of $2.51 billion also exceeding the forecast of $2.42 billion, leading to a 3% increase in stock price, reflecting market confidence in its performance.
- Target's Optimistic Sales Outlook: Target reported first-quarter earnings of $1.71 per share on revenue of $25.44 billion, both exceeding analyst expectations, resulting in a nearly 2% stock price increase, and the company raised its full-year sales outlook, indicating confidence in future growth.
- Cava Guidance Upgrade: Cava raised its full-year adjusted EBITDA guidance to between $181 million and $191 million, with shares jumping nearly 7%, while first-quarter earnings of 20 cents per share and $438 million in revenue also beat expectations, showcasing strong market performance.
See More
Investors Eye Nvidia Earnings and FDA Approval for ImmunityBio
- Nvidia Earnings Anticipation: Investors are eagerly awaiting Nvidia's upcoming earnings report, with the market questioning whether the AI rally can continue to exceed high expectations; Nvidia represents the largest short position in the S&P 500, reflecting significant market focus on its future performance amid standard 'beat and raise' expectations.
- FDA Drug Approval: ImmunityBio's supplemental biologics license application for ANKTIVA plus BCG has been accepted by the FDA, leading to a 4% premarket stock surge, marking a significant advancement in bladder cancer treatment and setting a regulatory action date for January 6, 2027.
- Oil Prices and Geopolitics: Oil prices remain elevated due to supply concerns tied to tensions in the Strait of Hormuz, exacerbating investor worries about inflation, particularly following a spike in the 10-year Treasury yield, which has contributed to a cautious market sentiment regarding economic outlook.
- Market Sentiment and ETF Performance: Despite market volatility, retail sentiment towards ETFs like SPDR S&P 500 ETF (SPY) and Invesco QQQ Trust (QQQ) remains 'extremely bullish', indicating sustained investor confidence in tech stocks, especially as the earnings season approaches.
See More
CAVA Group Reports Strong Q1 2026 Earnings with Strategic Growth Initiatives
- Significant Revenue Growth: CAVA reported a 32.2% year-over-year revenue increase in Q1 2026, reaching $434.4 million, with same-store sales up 9.7%, demonstrating strong customer traffic growth that solidifies its leadership in the Mediterranean cuisine sector.
- New Product Launch: The introduction of Pomegranate-Glazed Salmon marks CAVA's first seafood offering, which has shown promising early results across all restaurants nationwide, expected to generate new revenue streams and enhance brand appeal.
- Optimistic Future Outlook: Management raised the forecast for new restaurant openings in 2026 from 74-76 to 75-77, while also increasing same-store sales expectations to 4.5%-6.5%, reflecting confidence in market demand and a proactive expansion strategy.
- Strong Financial Health: CAVA's restaurant profit for Q1 was $108.9 million, or 25.1% of revenue, with robust cash flow performance showing $64.1 million from operations, indicating the company maintains financial stability amid its expansion efforts.
See More
Cava (CAVA) Q1 2026 Earnings Call Transcript
See More
CAVA Group Reports Strong Q1 Earnings and Upbeat Outlook
- Significant Revenue Growth: CAVA's Q1 revenue surged 32.2% year-on-year to $434.4 million, driven by strong same-store sales and new restaurant openings, showcasing the company's resilience amid economic uncertainty.
- Increased Customer Traffic: The chain experienced a 6.8% rise in guest traffic during the quarter, a notable achievement against a backdrop of cautious consumer spending and geopolitical concerns, indicating successful brand appeal and market positioning.
- Robust Pricing Strategy: CEO Brett Schulman highlighted that CAVA's price increases since 2019 have remained below inflation, playing a crucial role in building customer trust and long-term loyalty while avoiding discounting tactics employed by competitors.
- Optimistic Outlook: CAVA raised its full-year same-restaurant sales forecast to a range of 4.5% to 6.5%, exceeding the previous guidance of 3% to 5%, reflecting strong confidence in future growth and robust market demand.
See More
Cava Group's Price Target Raised to $98 by Analysts
- Price Target Increase: Baird raised Cava's price target from $88 to $98 while maintaining an 'Outperform' rating, reflecting analysts' confidence in the company's future performance.
- Strong Q1 Performance: Cava reported first-quarter revenue of $434.4 million, a 32.2% year-over-year increase, with same-store sales growth of 9.7%, showcasing the company's success in new restaurant openings and customer traffic growth.
- Analyst Optimism: Stifel analyst Chris O'Cull raised Cava's price target to $105, expecting sustained unit productivity and brand awareness to support the stock's premium valuation, indicating strong market confidence in future growth.
- Retail Sentiment Shift: Retail sentiment for Cava on Stocktwits shifted from 'bullish' to 'extremely bullish', with message volumes significantly increasing, reflecting investor optimism about the company's prospects.
See More
Multiple Companies Beat Earnings Estimates, Stock Movements
- Lowe's Earnings Report: Despite slightly beating earnings and revenue estimates in its first-quarter report, Lowe's shares fell nearly 2%, indicating that challenges in the macro housing market are impacting investor sentiment.
- Toll Brothers Strong Performance: Toll Brothers reported fiscal second-quarter earnings of $2.72 per share, surpassing the $2.57 expected by analysts, with revenue of $2.51 billion also exceeding the forecast of $2.42 billion, leading to a 3% increase in stock price, reflecting market confidence in its performance.
- Target's Optimistic Sales Outlook: Target reported first-quarter earnings of $1.71 per share on revenue of $25.44 billion, both exceeding analyst expectations, resulting in a nearly 2% stock price increase, and the company raised its full-year sales outlook, indicating confidence in future growth.
- Cava Guidance Upgrade: Cava raised its full-year adjusted EBITDA guidance to between $181 million and $191 million, with shares jumping nearly 7%, while first-quarter earnings of 20 cents per share and $438 million in revenue also beat expectations, showcasing strong market performance.
See More
Investors Eye Nvidia Earnings and FDA Approval for ImmunityBio
- Nvidia Earnings Anticipation: Investors are eagerly awaiting Nvidia's upcoming earnings report, with the market questioning whether the AI rally can continue to exceed high expectations; Nvidia represents the largest short position in the S&P 500, reflecting significant market focus on its future performance amid standard 'beat and raise' expectations.
- FDA Drug Approval: ImmunityBio's supplemental biologics license application for ANKTIVA plus BCG has been accepted by the FDA, leading to a 4% premarket stock surge, marking a significant advancement in bladder cancer treatment and setting a regulatory action date for January 6, 2027.
- Oil Prices and Geopolitics: Oil prices remain elevated due to supply concerns tied to tensions in the Strait of Hormuz, exacerbating investor worries about inflation, particularly following a spike in the 10-year Treasury yield, which has contributed to a cautious market sentiment regarding economic outlook.
- Market Sentiment and ETF Performance: Despite market volatility, retail sentiment towards ETFs like SPDR S&P 500 ETF (SPY) and Invesco QQQ Trust (QQQ) remains 'extremely bullish', indicating sustained investor confidence in tech stocks, especially as the earnings season approaches.
See More
CAVA Group Reports Strong Q1 2026 Earnings with Strategic Growth Initiatives
- Significant Revenue Growth: CAVA reported a 32.2% year-over-year revenue increase in Q1 2026, reaching $434.4 million, with same-store sales up 9.7%, demonstrating strong customer traffic growth that solidifies its leadership in the Mediterranean cuisine sector.
- New Product Launch: The introduction of Pomegranate-Glazed Salmon marks CAVA's first seafood offering, which has shown promising early results across all restaurants nationwide, expected to generate new revenue streams and enhance brand appeal.
- Optimistic Future Outlook: Management raised the forecast for new restaurant openings in 2026 from 74-76 to 75-77, while also increasing same-store sales expectations to 4.5%-6.5%, reflecting confidence in market demand and a proactive expansion strategy.
- Strong Financial Health: CAVA's restaurant profit for Q1 was $108.9 million, or 25.1% of revenue, with robust cash flow performance showing $64.1 million from operations, indicating the company maintains financial stability amid its expansion efforts.
See More
Cava (CAVA) Q1 2026 Earnings Call Transcript
See More
